MCID: DFF019
MIFTS: 43

Diffuse Gastric Cancer

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Diffuse Gastric Cancer

MalaCards integrated aliases for Diffuse Gastric Cancer:

Name: Diffuse Gastric Cancer 52
Signet Ring Cell Gastric Carcinoma 52
Diffuse Gastric Cancer Syndrome 29
Signet Ring Gastric Carcinoma 52
Gastric Signet Ring Carcinoma 71
Carcinoma, Signet Ring Cell 71
Signet Ring Cell Carcinoma 52
Signet Cell Adenocarcinoma 52
Cancer, Gastric, Diffuse 39

Classifications:



External Ids:

UMLS 71 C0206696 C2064167

Summaries for Diffuse Gastric Cancer

NIH Rare Diseases : 52 Diffuse gastric cancer is a type of cancer found most often in the glandular cells lining the stomach, but can also develop in the bowel, breast, pancreas, bladder, prostate or lung. The 2010 WHO (World Health Organization) classification recognizes four major histologic patterns of gastric cancers: tubular, papillary, mucinous and poorly cohesive (including signet ring cell carcinoma), plus uncommon histologic variants. The term "signet ring cell" is often used because the cells look like signet rings when viewed under a microscope. The signet cells are a type of epithelial cell. Epithelial tissue is skin tissue , covering and lining the body both inside and out. When diffuse gastric cancer is inherited it is called "hereditary diffuse gastric cancer." Treatment depends on the stage at which the cancer is found and may include chemotherapy , radiation therapy , or operations to remove the stomach (gastrectomy).

MalaCards based summary : Diffuse Gastric Cancer, also known as signet ring cell gastric carcinoma, is related to gastric cancer, hereditary diffuse and signet ring cell adenocarcinoma. An important gene associated with Diffuse Gastric Cancer is CDH1 (Cadherin 1), and among its related pathways/superpathways are TGF-Beta Pathway and ERK Signaling. The drugs Cisplatin and Tegafur have been mentioned in the context of this disorder. Affiliated tissues include prostate, breast and lung.

Related Diseases for Diffuse Gastric Cancer

Diseases in the Diffuse Gastric Cancer family:

Gastric Cancer, Hereditary Diffuse

Diseases related to Diffuse Gastric Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 293)
# Related Disease Score Top Affiliating Genes
1 gastric cancer, hereditary diffuse 33.5 KRAS CTNNA1 CDH1
2 signet ring cell adenocarcinoma 30.6 KRAS CDH1
3 papillary adenocarcinoma 30.2 KRAS CDH1
4 pseudomyxoma peritonei 30.0 KRAS CDH1
5 bronchiolo-alveolar adenocarcinoma 29.9 KRAS CDH1
6 endometrial adenocarcinoma 29.9 KRAS CDH1
7 teratoma 29.9 KRAS CDH1
8 carcinosarcoma 29.9 KRAS CDH1
9 intrahepatic cholangiocarcinoma 29.8 KRAS CDH1
10 gastric adenocarcinoma 29.7 KRAS CTNNA1 CDH1
11 cholangiocarcinoma 29.4 KRAS CTNNA1 CDH1
12 colorectal adenocarcinoma 29.3 KRAS CDH1
13 familial adenomatous polyposis 29.2 KRAS CDH1
14 bile duct signet ring cell carcinoma 12.7
15 pancreatic signet ring cell adenocarcinoma 12.1
16 prostate signet ring cell adenocarcinoma 12.0
17 ampullary signet ring cell adenocarcinoma 12.0
18 breast signet ring cell adenocarcinoma 12.0
19 gastric cancer 11.9
20 gallbladder signet ring cell adenocarcinoma 11.9
21 krukenberg carcinoma 11.8
22 prostate cancer 11.8
23 prostate cancer, hereditary, 1 11.5
24 prostate cancer, hereditary, 12 11.5
25 prostate cancer, hereditary, 13 11.5
26 prostate cancer, hereditary, 11 11.5
27 prostate cancer, hereditary, 2 11.5
28 mucinous adenocarcinoma 10.8
29 rare tumor 10.7
30 appendix adenocarcinoma 10.7
31 obstructive jaundice 10.6
32 bladder cancer 10.5
33 tubular adenocarcinoma 10.5
34 transitional cell carcinoma 10.5
35 adenoma 10.5
36 eyelid carcinoma 10.4
37 rectum cancer 10.4
38 intestinal obstruction 10.4
39 colorectal cancer 10.4
40 respiratory failure 10.4
41 disseminated intravascular coagulation 10.4
42 hemopericardium 10.4
43 pericardial effusion 10.4
44 appendicitis 10.4
45 thrombotic microangiopathy 10.4
46 hydronephrosis 10.3
47 cardiac tamponade 10.3
48 bladder adenocarcinoma 10.3
49 hemolytic anemia 10.3
50 ileus 10.3

Graphical network of the top 20 diseases related to Diffuse Gastric Cancer:



Diseases related to Diffuse Gastric Cancer

Symptoms & Phenotypes for Diffuse Gastric Cancer

Drugs & Therapeutics for Diffuse Gastric Cancer

Drugs for Diffuse Gastric Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 74)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Tegafur Approved, Investigational Phase 3 17902-23-7 5386
3
Irinotecan Approved, Investigational Phase 3 97682-44-5, 100286-90-6 60838
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Fluorouracil Approved Phase 3 51-21-8 3385
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
7
Bevacizumab Approved, Investigational Phase 3 216974-75-3
8
Oxaliplatin Approved, Investigational Phase 3 61825-94-3 5310940 9887054 6857599 43805
9
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
10
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
11
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
12
Camptothecin Experimental Phase 3 7689-03-4
13 Immunologic Factors Phase 3
14 topoisomerase I inhibitors Phase 3
15 Tetrahydrofolates Phase 3
16 Topoisomerase Inhibitors Phase 3
17 Formyltetrahydrofolates Phase 3
18 Cola Phase 3
19 Immunosuppressive Agents Phase 3
20 Trace Elements Phase 3
21 Vitamins Phase 3
22 Endothelial Growth Factors Phase 3
23 Micronutrients Phase 3
24 Vitamin B Complex Phase 3
25 Angiogenesis Inhibitors Phase 3
26 Vitamin B9 Phase 3
27 Mitogens Phase 3
28 Folate Phase 3
29 Hematinics Phase 3
30 Immunoglobulin G Phase 3
31 Calcium, Dietary Phase 3
32 Protective Agents Phase 3
33 Antidotes Phase 3
34 Nutrients Phase 3
35 Protein Kinase Inhibitors Phase 3
36 Antimetabolites Phase 3
37
Apatinib Phase 3 811803-05-1
38
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
39
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
40
Curcumin Approved, Experimental, Investigational Phase 2 458-37-7 969516
41
Turmeric Approved, Experimental, Investigational Phase 2
42
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
43
nivolumab Approved Phase 2 946414-94-4
44
Talimogene laherparepvec Approved, Experimental, Investigational Phase 2 1187560-31-1
45 Estrogens Phase 2
46 Pharmaceutical Solutions Phase 2
47 Estrogen Receptor Antagonists Phase 2
48 Antineoplastic Agents, Hormonal Phase 2
49 Estrogen Antagonists Phase 2
50 Analgesics Phase 2

Interventional clinical trials:

(show all 23)
# Name Status NCT ID Phase Drugs
1 An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy Unknown status NCT01285557 Phase 3 S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm);Fluorouracil/cisplatin (control arm)
2 Intergroup Randomized Phase III Study of Postoperative Irinotecan, 5-Fluorouracil and Leucovorin vs. Oxaliplatin, 5-Fluorouracil and Leucovorin vs. 5-Fluorouracil and Leucovorin for Patients With Stage II or III Rectal Cancer Receiving Either Preoperative Radiation and 5-Fluorouracil or Postoperative Radiation and 5-Fluorouracil Completed NCT00068692 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin;Irinotecan
3 A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin Versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers Active, not recruiting NCT00217737 Phase 3 Fluorouracil;Leucovorin Calcium;Oxaliplatin
4 A Randomized, Multicenter, Controlled Study of XELOX (Oxaliplatin With Capecitabine) Combined With Apatinib Versus XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring Carcinoma With D2 Dissection. Not yet recruiting NCT03355612 Phase 3 Apatinib;XELOX
5 A Phase 2 Study of MK-2206 in Previously Treated Metastatic Colorectal Cancer Patients Enriched for PTEN Loss and PIK3CA Mutation Completed NCT01802320 Phase 2 Akt Inhibitor MK2206
6 Phase II Study Evaluating Confocal Endoscopic Microscopy for Detection of Early Stage Gastric Cancer in Subjects With Hereditary Diffuse Gastric Cancer Syndrome Recruiting NCT03648879 Phase 2
7 Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer or Diffuse Gastric Cancer Recruiting NCT03620643 Phase 2 Crizotinib Oral Capsule [Xalkori];Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex]
8 A Randomized Double Blinded Study of Curcumin With Pre-operative Capecitabine and Radiation Therapy Followed by Surgery for Rectal Cancer Active, not recruiting NCT00745134 Phase 2 Capecitabine
9 Efficacy of Adding Trastuzumab to Standard Chemotherapy in Patients With Advanced HER2-negative Gastric Cancer and HER2 Positive Expression in Circulating Tumor Cells Not yet recruiting NCT04168931 Phase 2 Trastuzumab
10 A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors Suspended NCT02978625 Phase 2
11 Phase 1 With Expansion Cohorts in a Study of NEO-201 in Adults With Chemo-Resistant Solid Tumors Recruiting NCT03476681 Phase 1 NEO-201
12 Phase I Study: Nab-paclitaxel Combined With S-1 Treating Diffuse Type of Stage Ⅲ Gastric Cancer as Adjuvant Setting (NORDICA) Not yet recruiting NCT03977220 Phase 1 Nab-paclitaxel combined with S-1
13 Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer Terminated NCT01198535 Phase 1 Gamma-Secretase Inhibitor RO4929097
14 Prospective Study of Colorectal Cancer Comparing the Surface With the Invasive Front Unknown status NCT02002299
15 Epidemiological, Clinical and Pathological Characteristics of Gastric Tumors. The Population Based Specialized Registry in Northern Italy Unknown status NCT01662739
16 Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas? Completed NCT01249859
17 Single-bite Versus Double-bite Technique for Mapping Biopsies During Endoscopic Surveillance of Hereditary Diffuse Gastric Cancer: a Single Center, Randomized Controlled Trial Completed NCT03950908
18 Signet Ring Cells in Esophageal and GE Junction Carcinomas Have a More Aggressive Biological Behavior Completed NCT01824966
19 Efficacy of Narrow Band Imaging Technique for Identifying Resection Margin Status After Gastrectomy for Gastric Cancer Completed NCT02926716
20 Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer Recruiting NCT03030404
21 Screening for Familial Gastric Cancer in First Degree Relatives Terminated NCT01727908
22 The Metabolic Consequences of Gastrointestinal Surgery Terminated NCT02836353 Somatostatin;Rifaximin
23 Endodrill vs. Conventional Biopsy. Evaluation of Diagnostic Capacity in Diffuse Gastric Cancer Withdrawn NCT02594943

Search NIH Clinical Center for Diffuse Gastric Cancer

Genetic Tests for Diffuse Gastric Cancer

Genetic tests related to Diffuse Gastric Cancer:

# Genetic test Affiliating Genes
1 Diffuse Gastric Cancer Syndrome 29

Anatomical Context for Diffuse Gastric Cancer

MalaCards organs/tissues related to Diffuse Gastric Cancer:

40
Prostate, Breast, Lung, Skin, Pancreas, Colon, Testes

Publications for Diffuse Gastric Cancer

Articles related to Diffuse Gastric Cancer:

(show top 50) (show all 445)
# Title Authors PMID Year
1
Endoscopic Ultrasound Has Limited Utility in Diagnosis of Gastric Cancer in Carriers of CDH1 Mutations. 61
31077828 2020
2
A New Rho(d) Map to Diffuse Gastric Cancer. 61
32024682 2020
3
Gain-of-Function RHOA Mutations Promote Focal Adhesion Kinase Activation and Dependency in Diffuse Gastric Cancer. 61
31771969 2020
4
Frequency and Clinical Characteristics of Unselected Korean Gastric Cancer Patients with a Germline CDH1 V832M Mutation. 61
31892987 2020
5
CD2AP inhibits metastasis in gastric cancer by promoting cellular adhesion and cytoskeleton assembly. 61
31989722 2020
6
Complete histopathologic examination of risk reduction gastrectomy specimens for CDH1 germline mutation: Is it warranted in routine clinical practice? 61
31986421 2020
7
CDH1 on multigene panel testing: Look before you leap. 61
31841163 2019
8
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793. 61
31764755 2019
9
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION, Number 793. 61
31764758 2019
10
Targeted versus random biopsies in surveillance endoscopy in Hereditary Diffuse Gastric Cancer Syndrome. 61
31887448 2019
11
Clinical features and cancer risk in families with pathogenic CDH1 variants irrespective of clinical criteria. 61
31296550 2019
12
Diagnostic value of negative enrichment and immune fluorescence in situ hybridization for intraperitoneal free cancer cells of gastric cancer. 61
31949396 2019
13
Integrated Analysis of Structural Variation and RNA Expression of FGFR2 and Its Splicing Modulator ESRP1 Highlight the ESRP1amp-FGFR2norm-FGFR2-IIIchigh Axis in Diffuse Gastric Cancer. 61
31881796 2019
14
Total Gastrectomy for CDH-1 Mutation Carriers: An Institutional Experience. 61
31685251 2019
15
Assessment of Diagnostic Outcomes of RNA Genetic Testing for Hereditary Cancer. 61
31642931 2019
16
Hereditary diffuse gastric cancer: cancer risk and the personal cost of preventive surgery. 61
31273560 2019
17
Surveillance Endoscopy in the Management of Hereditary Diffuse Gastric Cancer Syndrome. 61
31678201 2019
18
Identification of c.1531C>T Pathogenic Variant in the CDH1 Gene as a Novel Germline Mutation of Hereditary Diffuse Gastric Cancer. 61
31600923 2019
19
Hereditary Gastrointestinal Cancer Syndromes: Role of Imaging in Screening, Diagnosis, and Management. 61
31373866 2019
20
British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. 61
31278206 2019
21
Frequency of CDH1 germline variants and contribution of dietary habits in early age onset gastric cancer patients in Brazil. 61
30895400 2019
22
Allosteric AKT Inhibitors Target Synthetic Lethal Vulnerabilities in E-Cadherin-Deficient Cells. 61
31540244 2019
23
c-Met-dependent phosphorylation of RhoA plays a key role in gastric cancer tumorigenesis. 61
31056743 2019
24
Novel Variants and Copy Number Variation in CDH1 Gene in Iranian Patients with Sporadic Diffuse Gastric Cancer. 61
29577179 2019
25
A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. 61
31467357 2019
26
Genetic analysis of a case of Helicobacter pylori-uninfected intramucosal gastric cancer in a family with hereditary diffuse gastric cancer. 61
30542785 2019
27
Clinical implications of CTNNA1 germline mutations in asymptomatic carriers. 61
30515673 2019
28
Outcomes of Endoscopic Surveillance in Individuals With Genetic Predisposition to Hereditary Diffuse Gastric Cancer. 61
30935944 2019
29
Intestinal and diffuse gastric cancer: a retrospective study comparing primary sites. 61
30870726 2019
30
Geospatial analyses identify regional hot spots of diffuse gastric cancer in rural Central America. 61
31174492 2019
31
Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric Cancers. 61
31246251 2019
32
Optimal Timing of Total Gastrectomy to Prevent Diffuse Gastric Cancer in Individuals with Pathogenic Variants in CDH1. 61
31220641 2019
33
The role of endoscopy in the management of hereditary diffuse gastric cancer syndrome. 61
31249446 2019
34
Associations of CDH1 germline variant location and cancer phenotype in families with hereditary diffuse gastric cancer (HDGC). 61
30745422 2019
35
Evaluation of confocal endoscopic microscopy for detection of early-stage gastric cancer in hereditary diffuse gastric cancer (HDGC) syndrome. 61
31183189 2019
36
Establishing a center of excellence for hereditary diffuse gastric cancer syndrome. 61
30618047 2019
37
Early Hereditary Diffuse Gastric Cancer (eHDGC) is Characterized by Subtle Genomic Instability and Active DNA Damage Response. 61
30547291 2019
38
The benefits of a model of interval comprehensive assessments (MICA) in hereditary cancer Syndromes: Hereditary diffuse gastric cancer (HDGC) as an example. 61
31109593 2019
39
Cleft lip/palate and hereditary diffuse gastric cancer: report of a family harboring a CDH1 c.687 + 1G > A germline mutation and review of the literature. 61
30306390 2019
40
Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. 61
30302652 2019
41
Clinical spectrum and pleiotropic nature of CDH1 germline mutations. 61
30661051 2019
42
Immunistochemical Analysis of the Expression of TGFβ, Galectin-1, Vimentin, and Thrombospondin in Gastric Cancer Associated with Systemic Undifferentiated Connective Tissue Dysplasia. 61
31028580 2019
43
INC280 inhibits Wnt/β-catenin and EMT signaling pathways and its induce apoptosis in diffuse gastric cancer positive for c-MET amplification. 61
30871613 2019
44
E-cadherin-deficient cells have synthetic lethal vulnerabilities in plasma membrane organisation, dynamics and function. 61
30066183 2019
45
Is prophylactic gastrectomy indicated for healthy carriers of CDH1 gene mutations associated with hereditary diffuse gastric cancer? 61
30466290 2019
46
[Hereditary diffuse gastric cancer : case serie of 8 patients from a single family and literature review]. 61
30897312 2019
47
Patients' Medical and Psychosocial Experiences After Detection of a CDH1 Variant With Multigene Panel Testing. 61
31511843 2019
48
Multidisciplinary management of CDH1 germinal mutation and prophylactic management hereditary lobular breast cancer: A case report. 61
31028995 2019
49
CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management. 61
31853199 2019
50
Germline CDH1 mutations are a significant contributor to the high frequency of early-onset diffuse gastric cancer cases in New Zealand Māori. 61
29589180 2019

Variations for Diffuse Gastric Cancer

Cosmic variations for Diffuse Gastric Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88883557 APC breast,NS,carcinoma,tubular c.3316G>T p.G1106* 5:112838910-112838910 3
2 COSM88878282 APC breast,NS,carcinoma,tubular c.4390G>T p.E1464* 5:112839984-112839984 3
3 COSM88883255 APC breast,NS,carcinoma,tubular c.4495G>T p.G1499* 5:112840089-112840089 3
4 COSM88918678 APC breast,NS,carcinoma,tubular c.5047G>T p.E1683* 5:112840641-112840641 3
5 COSM122392651 breast,NS,carcinoma,tubular c.4390G>T p.E1464* 5:112839984-112839984 3
6 COSM122398497 breast,NS,carcinoma,tubular c.4495G>T p.G1499* 5:112840089-112840089 3
7 COSM122398803 breast,NS,carcinoma,tubular c.3316G>T p.G1106* 5:112838910-112838910 3
8 COSM122438481 breast,NS,carcinoma,tubular c.5047G>T p.E1683* 5:112840641-112840641 3

Expression for Diffuse Gastric Cancer

Search GEO for disease gene expression data for Diffuse Gastric Cancer.

Pathways for Diffuse Gastric Cancer

Pathways related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

(show all 25)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.14 KRAS CDH1 CCL8 CCL7
2
Show member pathways
13.12 KRAS CTNNA1 CDH1 CCL8 CCL7
3
Show member pathways
12.93 KRAS CTNNA1 CCL8 CCL7
4
Show member pathways
12.64 KRAS CTNNA1 CDH1
5
Show member pathways
12.57 KRAS CTNNA1 CDH1
6
Show member pathways
12.52 KRAS CCL8 CCL7
7
Show member pathways
12.51 KRAS CTNNA1 CDH1
8 12.47 KRAS CTNNA1 CDH1
9
Show member pathways
12.35 KRAS CTNNA1 CDH1
10
Show member pathways
12.28 KRAS CTNNA1 CDH1
11
Show member pathways
12.09 KRAS CTNNA1 CDH1 CCL8 CCL7
12
Show member pathways
12 KRAS CTNNA1 CDH1
13 11.71 KRAS CDH1
14 11.71 CTNNA1 CDH1
15 11.42 KRAS CDH1
16 11.41 CTNNA1 CDH1
17 11.39 CTNNA1 CDH1
18 11.1 CTNNA1 CDH1
19 11.03 CTNNA1 CDH1
20 11.01 CTNNA1 CDH1
21 10.89 CTNNA1 CDH1
22 10.72 CTNNA1 CDH1
23 10.66 CDH1 CCL8 CCL7
24 10.43 CTNNA1 CDH1
25 10.07 CTNNA1 CDH1

GO Terms for Diffuse Gastric Cancer

Cellular components related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell-cell adherens junction GO:0005913 9.26 CTNNA1 CDH1
2 adherens junction GO:0005912 9.16 CTNNA1 CDH1
3 catenin complex GO:0016342 8.96 CTNNA1 CDH1
4 flotillin complex GO:0016600 8.62 CTNNA1 CDH1

Biological processes related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cellular calcium ion homeostasis GO:0006874 9.48 CCL8 CCL7
2 cellular response to interferon-gamma GO:0071346 9.46 CCL8 CCL7
3 neutrophil chemotaxis GO:0030593 9.43 CCL8 CCL7
4 cellular response to interleukin-1 GO:0071347 9.4 CCL8 CCL7
5 chemokine-mediated signaling pathway GO:0070098 9.37 CCL8 CCL7
6 monocyte chemotaxis GO:0002548 9.32 CCL8 CCL7
7 adherens junction organization GO:0034332 9.26 CTNNA1 CDH1
8 lymphocyte chemotaxis GO:0048247 9.16 CCL8 CCL7
9 eosinophil chemotaxis GO:0048245 8.96 CCL8 CCL7
10 cellular response to indole-3-methanol GO:0071681 8.62 CTNNA1 CDH1

Molecular functions related to Diffuse Gastric Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 beta-catenin binding GO:0008013 9.26 CTNNA1 CDH1
2 chemokine activity GO:0008009 9.16 CCL8 CCL7
3 CCR chemokine receptor binding GO:0048020 8.96 CCL8 CCL7
4 gamma-catenin binding GO:0045295 8.62 CTNNA1 CDH1

Sources for Diffuse Gastric Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....